• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pacira prices $300m senior notes offering

March 8, 2017 By Sarah Faulkner

Pacira prices $300m senior notes offeringPacira Pharmaceuticals (NSDQ:PCRX) said today that it priced $300 million of convertible 2.375% senior notes due 2022 in a private placement to qualified institutional buyers.

The Parsippany, N.J.-based company also gave purchasers a 30-day option to buy an additional $45 million aggregate principal amount of notes.

The company expects to bring in about $290 million in net proceeds from the offering. Pacira said it plans to use a portion of the proceeds to exchange $112 million of its existing 3.25% convertible senior notes due 2019 for a combination of cash and shares of Pacira common stock. The remaining proceeds will be used for general corporate purposes, including research and development, according to Pacira.

In November last year, Touch Surgery and Pacira launched the Exparel knee training simulation for the Touch Surgery app, designed to provide clinicians with a virtual training experience for administering the bupivacaine liposome injectable suspension in total knee arthroplasty.

The simulation includes a 3D environment where clinical decisions and viewpoints are all dictated by the user and simulates the total knee arthroplasty surgical environment. The goal of the training is to teach the user how to properly mix and inject Exparel into the surgical site. Users can manipulate the angle of the needle, the site of the injection and the amount of fluid ejected at the site.

Pacira’s Exparel is a long-acting, local analgesic used to manage post-surgical pain and was commercially launched in the U.S. in April 2012. The company suggested that Exparel can help reduce patients’ post-surgical pain and opioid requirements. Pacira also markets DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure for targeted and sustained release.

Filed Under: Featured, Funding Roundup, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Pacira Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS